Chronic kidney disease (CKD) patients have an increased risk of cardiovascular diseases
(CVDs). The present study aimed to investigate the gut microbiota and blood trimethylamine …

Rationale: Trimethylamine-N-oxide (TMAO), a gut microbial-dependent metabolite of dietary
choline, phosphatidylcholine (lecithin), and l-carnitine, is elevated in chronic kidney …

Patients with chronic kidney disease (CKD) have elevated circulating levels of
trimethylamine N-oxide (TMAO), a metabolite derived from gut microbes and associated with …

Gut microbiota-dependent Trimethylamine-N-oxide (TMAO) has been reported to be strongly
linked to renal function and to increased cardiovascular events in the general population …

Elevated circulating trimethylamine N-oxide (TMAO) concentrations have been observed in
patients with chronic kidney disease (CKD). We aimed to systematically estimate and …

The gut microbiota plays a pivotal role in the onset and development of diabetes and its
complications. Trimethylamine N-oxide (TMAO), a gut microbiota-dependent metabolite of …

Trimethylamine-N-oxide (TMAO), a gut microbiota-produced metabolite, is accumulated in
chronic kidney disease (CKD) patients. It is well known to contribute to CKD-related …

Objective: Gut microbial metabolism of dietary choline, a nutrient abundant in a Western diet,
produces trimethylamine (TMA) and the atherothrombosis-and fibrosis-promoting metabolite …

The gut microbiota and its metabolites have become a hotspot of recent research.
Trimethylamine N-oxide (TMAO) metabolized by the gut microbiota is closely related to …

Trimethylamine-N-oxide (TMAO) is a product of dietary, gut microbiome, and tissues
metabolism. Elevated blood TMAO levels are associated with heart attack, stroke and …